CSIG-17. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT

INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor. With limited effective therapeutic strategies, prognosis for GBM is very poor. Our previous study shows that the expression of Protein Arginine Methyltransferase 5 (PRMT5) is upregulated in GBM; its inhibition promote...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Otani, Yoshihiro, Namagiri, Sriya, Thammegowda, Shilpa, Sur, Hannah, Chowdhury, Ashis, Lewis, Cole, Shimizu, Toshihiko, Lee, Tae Jin, Maric, Dragan, Yoo, Ji Young, Heiss, John, Kaur, Balveen, Banasavadi-Siddegowda, Yeshavanth Kumar
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Cell Signaling and Signaling Pathways
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650434/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.129
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares